Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

BaseLaunch (BaselArea.swiss). (9/28/20). "Press Release: BaseLaunch Announces that Johnson & Johnson Innovation Has Renewed Its Commitment Becoming Latest Strategic Partner in the Second Phase". Basel.

Region Region Basel BS
  Country Switzerland
Organisations Organisation BaseLaunch Accelerator (Basel)
  Group Basel (govt city)
  Organisation 2 Cilag GmbH International (CH)
  Group Johnson & Johnson (JnJ) (Group)
Products Product business development (state/region)
  Product 2 pharmaceutical
Persons Person Scott, Nerida (JnJ 202009 Head JnJ Innovation EMEA)
  Person 2 Emmerth, Stephan (BaseLaunch 202009 Director BusDev + Operations at BaseLaunch)
     


BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces their renewed strategic partnership with Cilag GmbH International, one of the pharmaceutical companies of Johnson & Johnson, who becomes the latest company to join the second phase of BaseLaunch's endeavor to fuel the next generation of biotech companies. The agreement was facilitated by Johnson & Johnson Innovation.

Johnson & Johnson Innovation, which supported BaseLaunch’s first phase, joins recently announced healthcare, pharma, venture fund and biotechnology strategic partners, including Roche, BB Pureos Bioventures, R oivant Sciences, Bridge Biotherapeutics and CSL Behring, in supporting BaseLaunch's investment in life sciences innovation.

Nerida Scott, Head, Johnson & Johnson Innovation, EMEA, commented: “Incubators and accelerators are central to the global healthcare startup ecosystem. We have been collaborating with BaseLaunch since launch in supporting the growth and development of early-stage biotech ventures and recognize the contribution the team has made towards achieving their goals. We are delighted to continue to support BaseLaunch Phase II in its mission to launch the next generation of breakthrough scientific innovation.”

Stephan Emmerth, Director of Business Development & Operations BaseLaunch, added: “We are delighted that Johnson & Johnson Innovation is continuing its collaboration with BaseLaunch. Working together with our dynamic group of international and entrepreneurial partners, BaseLaunch Phase II will support cutting-edge early-stage biotechs to achieve financing and grow their therapeutic ventures in the Basel Area.”

BaseLaunch is an accelerator and incubator for early stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A funding, providing financing and supporting all aspects of business development. During 2018 and 2019, BaseLaunch supported nine early therapeutic ventures which have raised over USD 100 million in equity capital from US and European venture funds, thereby contributing to the life sciences ecosystem of the Basel Area. Recently, BaseLaunch has added another four ventures to its portfolio, and has been instrumental in contributing to the development of six more ventures in the Basel Area. Building on the success of its first phase, BaseLaunch Phase II increased funding per venture to a maximum of USD 0.5 million (versus USD 0.25 million previously) and now accepts applications allyear round, establishing BaseLaunch as a permanent initiative and the premier partner of choice for scientists and entrepreneurs that want to build potentially lif e-saving therapeutic ventures.


BaseLaunch is operated by Basel Area Business & Innovation, the investment and innovation promotion agency of the Basel Area. During its first phase (2017-2019), BaseLaunch was supported by Roche, Novartis Venture Fund, Johnson & Johnson Innovation, Pfizer and Roivant Sciences. Having entered its second phase, BaseLaunch is gearing up with new commitments, harnessing the Basel Area’s unique position as a global life sciences hub, as well as its rising popularity among investors, to attract the next generation of breakthrough companies. BaseLaunch Phase II is now open for applications. Interested groups can find information at www.baselaunch.ch/apply/.


For further information please contact:

BaseLaunch

Martin Jordan
Phone. +41 612 95 50 25, +41 7 6345 66 08
Email: martin.jordan@baselarea.swiss

Optimum Strategic Communications

Supriya Mathur, Charlotte Hepburne-Scott
Phone: +442 03 922 0891
Email: BaseLaunch@optimumcomms.com


About BaseLaunch

BaseLaunch is the Basel Area-bas ed incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. BaseLaunch serves as a growth platform for early stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A f unding, providing financing and supporting all aspects of bus iness development. Operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency of the Basel Area, BaseLaunch partners with leading global pharma companies and venture funds – those announced to date being Roche, BB Pur eos Bioventures, Roivant Sciences, Bridge Biotherapeutics and CSL Behr ing – which also feed into the pool out of which BaseLaunch funds ventures. Regional and domain partners include the cantons of Bas el-Landschaft, Bas el-Stadt and Jura as well as Alloy Therapeutics, KPMG, SpiroChem, Vos sius & Partner and Infors HT. Since 2018, BaseLaunch supported ventures have raised over USD 100 million. Harnessing Basel Area’s unique position as a global life sciences hub, as well as its rising popularity among investors, BaseLaunch is looking to attract the next generation of breakthrough companies. Interested groups can find more information at www.baselaunch.ch


About Basel Area Business & Innovation

Basel Area Business & Innovation is the investment and innovation promotion agency dedicated to helping companies, institutions and startups find business success in the Basel Area. The organization targets and attracts companies to settle, supports founders of innovative ventures, and drives high growth initiatives in order to establish the region as the Swis s business and innovation hub of the future. The non-profit agency focuses on growing the area’s cutting-edge industries life sciences, healthcare and production technologies and manages the Switzerland Innovation Park Basel Ar ea which houses the organization’s accelerator programs. The agency serves the cantons of Basel-Landschaft, Basel-Stadt and Jura.
www.baselarea.swiss


Basel Area Business & Innovation
Dufourstrasse 11
4010 Basel
Switzerland
Phone + 41 61 295 50 00
info®baselarea.swiss
www.baselarea.swiss

   
Record changed: 2020-10-21

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Basel (govt city)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top